Flputnam Investment Management Co. Has $8.11 Million Position in Pfizer Inc. (NYSE:PFE)

Flputnam Investment Management Co. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 3.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 281,648 shares of the biopharmaceutical company’s stock after selling 10,089 shares during the period. Flputnam Investment Management Co.’s holdings in Pfizer were worth $8,109,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Moneta Group Investment Advisors LLC increased its stake in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley lifted its position in shares of Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after buying an additional 348,628 shares during the last quarter. Norges Bank bought a new stake in shares of Pfizer during the 4th quarter worth about $3,150,472,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Trading Down 0.2 %

Shares of Pfizer stock traded down $0.04 during trading hours on Tuesday, hitting $25.87. The company’s stock had a trading volume of 3,840,978 shares, compared to its average volume of 42,205,949. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.33. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market capitalization of $146.49 billion, a PE ratio of 71.94, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The stock has a 50 day moving average of $27.27 and a 200 day moving average of $28.84.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.